Journal of Clinical Oncology
Articles in this Issue
First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): A phase 1 safety expansion.
1066 Background: BGB-43395, a highly selective CDK4i, showed preclinical antitumor activity characterized by improved CDK4...
A multicenter randomized controlled clinical study of neoadjuvant combination of axitinib plus toripalimab to improve disease-free survival of patients with renal cell carcinoma.
TPS4630 Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, accounting...
Clinical characteristics and prognostic analysis of epidermal growth factor receptor–mutated non–small cell lung cancer patients with malignant pleural effusion.
e20755 Background: Malignant pleural effusion (MPE) is common in advanced non-small cell lung cancer (NSCLC) and typically...
Disparities in mycosis fungoides outcomes: A multivariate survival and prevalence study.
e19117 Background: Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma. It is characterized by the...
Fusion-positive early-stage and locally advanced lung cancers: A real-world analysis of event-free, disease-free, and overall survival.
8036 Background: Fusion-positive lung cancers are a distinct subset of lung cancers. While outcomes in metastatic disease...
Role of palliative care nurse coordination in symptom control and care planning.
12063 Background: Effective coordination by palliative care nurses plays a central role in improving communication, sympto...
Pregnancy and cancer: A retrospective case series of obstetric, oncologic, and care-compliance outcomes.
e13549 Background: Two million women of reproductive age are diagnosed with cancer annually. Advances in cancer therapies...
Benefits of utilizing experiential learning in a medical school cancer survivorship course.
9018 Background: Cancer survivorship care remains underemphasized in medical education despite a growing population of can...
Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study.
e16070 Background: Our preliminary results suggested potential synergistic activity of fruquintinib combined with camreliz...
Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results.
2564 Background: Denileukin diftitox-cxdl (E7777) is an FDA-approved direct cytotoxic agent that depletes T-regulatory cel...
Integrating personalized ctDNA into clinical surveillance of soft tissue sarcoma: Performance, timing, and histologic insights.
11581 Background: Soft tissue sarcoma (STS), particularly larger and biologically aggressive subtypes, carries a high risk...
Impact of mRNA COVID-19 vaccination on survival in pembrolizumab-treated stage IV colon cancer: A multi-institutional propensity-matched analysis.
e15624 Background: Colon cancer remains a leading cause of cancer-related mortality. While immune checkpoint inhibitors (I...
Clinical outcomes and safety of trifluridine–tipiracil with or without bevacizumab in metastatic colorectal cancer: A real-world study from Saudi Arabia.
e23415 Background: Trifluridine–tipiracil (TAS-102) is an established later-line therapy for metastatic colorectal cancer...